DAO

Diamine Oxidase (DAO, also known as amine oxidase, copper-containing 1, or AOC1 after its gene) is the primary enzyme responsible for breaking down extracellular Histamine, particularly histamine that enters the body through the gut.

What It Does

DAO catalyzes the oxidative deamination of histamine:

Histamine → imidazole acetaldehyde → imidazole acetic acid

The reaction requires copper as a cofactor and produces hydrogen peroxide as a byproduct. It’s an extracellular enzyme — it works outside of cells, in the gut lumen, the intestinal wall, and the bloodstream. This makes it the first line of defense against Dietary Histamine.

Where It’s Produced

DAO is primarily produced by enterocytes — the epithelial cells lining the small intestine, particularly in the duodenum and jejunum. It’s also produced in the kidneys and placenta (pregnancy dramatically increases DAO levels — up to 500-fold — which is why some women with Histamine Intolerance experience symptom improvement during pregnancy, particularly in the second and third trimesters; Maintz et al., Hum Reprod Update 2008, PMID 18499706).

The intestinal production site is critical: it means DAO activity is directly tied to gut health. Anything that damages the intestinal epithelium can reduce DAO production.

What Inhibits DAO

Alcohol: Ethanol is a competitive substrate for DAO — the enzyme preferentially metabolizes alcohol over histamine. Alcohol also directly damages enterocytes. This is why alcohol is a particularly potent trigger: it delivers histamine (in wine/beer), triggers mast cells as a liberator, AND blocks the enzyme that would clear the resulting histamine.

NSAIDs:

Common misconception

NSAIDs are widely cited as DAO inhibitors in clinical and patient literature. However, direct experimental testing (Alemany-Fornés et al., J Clin Med 2023, PMID 38068554; Leitner et al., Inflamm Res 2014) found that ibuprofen, aspirin, and diclofenac have no meaningful inhibitory effect on DAO activity in vitro. The clinical association between NSAIDs and worsened histamine symptoms is real but is better explained by the COX inhibition shunt (see Salicylates) and the observation that people with pre-existing DAO genetic variants (AOC1 polymorphisms) are more susceptible to NSAID hypersensitivity (Agúndez et al., Curr Drug Metab 2012, PMID 23152756). NSAIDs are still problematic in mast cell conditions — they just aren’t problematic because of DAO inhibition.

Gut inflammation: Inflammatory conditions that damage the intestinal lining — Crohn’s disease, celiac disease, SIBO, chronic Intestinal Permeability — reduce the enterocyte population that produces DAO. This creates a feedback loop: mast cell activation causes gut inflammation → gut inflammation reduces DAO → reduced DAO increases histamine levels → more mast cell activation.

Certain medications: The strongest evidence for drug-induced DAO inhibition exists for clavulanic acid, chloroquine, and certain cephalosporins (Leitner et al., Inflamm Res 2014, PMID 25034236; Maintz & Novak, Am J Clin Nutr 2007, PMID 17490952). Some antidepressants (amitriptyline), isoniazid, and some antiarrhythmics (verapamil) have been reported to inhibit DAO but with weaker evidence. Metoclopramide and other dopamine antagonists may also interfere.

Genetic variants: See below.

AOC1 Genetic Variants

The AOC1 gene encodes DAO. Several single nucleotide polymorphisms (SNPs) affect enzyme function:

• rs10156191 (T allele) — Reduced DAO activity. One of the most studied variants.
• rs1049742 (C allele) — Reduced DAO activity.
• rs1049793 (G allele) — Reduced DAO activity.

These variants are relatively common in the general population. Having one copy (heterozygous) reduces DAO capacity; having two copies (homozygous) reduces it further. But genetics sets the ceiling, not the floor — even with optimal genetics, the acquired inhibitors above can push functional DAO below symptomatic thresholds.

Genetic testing context

DAO genetic variants are testable through consumer genetics platforms (23andMe raw data includes these SNPs). Finding a variant confirms reduced genetic capacity but doesn’t diagnose Histamine Intolerance by itself — it’s one piece of a multi-factor puzzle. Conversely, having no known variants doesn’t rule out DAO insufficiency, because acquired causes (gut damage, medications) can suppress DAO independent of genetics.

DAO Serum Levels

DAO can be measured in blood (see DAO Serum Levels). Low serum DAO correlates with Histamine Intolerance but the test has limitations — serum levels reflect circulating DAO, not necessarily intestinal wall DAO activity. A normal serum level doesn’t guarantee adequate gut DAO function.

Relationship to HNMT

DAO handles extracellular histamine (gut, bloodstream). HNMT handles intracellular histamine (brain, liver, kidneys). They’re complementary systems. A person can have adequate DAO but insufficient HNMT, or vice versa, and the symptom profiles will differ — DAO deficiency manifests primarily as food-related and gut symptoms, while HNMT deficiency may contribute more to neurological symptoms.

DAO Supplementation

See DAO Supplements for the mechanics and limitations of oral DAO supplementation.